China Pharma Q3 Loss Widens to $1.9M; Going-Concern Warning Reiterated
CPHI sits 28% above its 52-week low of $0.382.
Summary
China Pharma's Q3 2026 net loss widened to $1.9 million from $0.7 million a year earlier, with a $496,808 patent impairment and a reiterated going-concern warning. Cash rose to $3.68 million only through a $4.38 million July stock sale and insider loans.
Key Events · Earnings and Guidance · CPHI
-
Q3 Loss Widens Sharply
Net loss was $1,901,677 for the three months ended September 30, 2026 versus $651,482 a year earlier; nine-month loss reached $4,502,948 versus $1,965,421.
-
Patent Impairment Hits Results
A $496,808 impairment was recorded on the Apremilast solid dispersion patent after a decline in the related product's market price; nine-month intangible amortization rose to $2,737,383 from $513,030.
-
Going-Concern Warning Reiterated
Current liabilities exceed current assets by $1.6 million and the accumulated deficit is $51.7 million; operating activities used $1,195,540 of cash in nine months.
-
Cash Boosted by Stock Sale and Loans
Cash reached $3,679,896 from $345,112 at year-end, funded by a July 2026 sale of 2,500,000 shares at $2.00 for $4,378,862 net and $1,569,351 of CEO advances.
Analysis · CPHI · Life Sciences
The quarterly loss more than doubled year over year, driven by a $2.74 million nine-month jump in intangible amortization from the February 2026 patent acquisitions and a $496,808 write-down of the Apremilast patent. Substantial doubt about the company's ability to continue as a going concern is again stated: current liabilities exceed current assets by $1.6 million and the accumulated deficit stands at $51.7 million. Cash of $3.68 million is up sharply, but only because of the July 2026 stock sale and CEO loans, not operations — operating activities burned $1.2 million in nine months. Shareholders also face a pending proxy request to authorize a reverse split of up to 1:50 to protect the NYSE American listing, which would follow the 1-for-10 split executed in April 2025.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPHI was trading at $0.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $22M. The 52-week trading range was $0.38 to $19.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.